Noriko Seko
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2.
Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: March 13, 2026
Efficacy and safety of canakinumab in patients with adult-onset Still's disease: Results from an open-label phase III study in Japan.
Journal: Modern rheumatology
Published: November 27, 2025
Safety and Effectiveness of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis in Japan: A Post-Marketing Surveillance Study.
Journal: Rheumatology and therapy
Published: November 06, 2025
Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies.
Journal: The Journal of allergy and clinical immunology
Published: June 16, 2025
Remibrutinib in Chronic Spontaneous Urticaria.
Journal: The New England journal of medicine
Published: March 05, 2025
Efficacy and Safety of Voretigene Neparvovec in RPE65-Retinopathy: Results of a Phase III Trial in Japan.
Journal: Ophthalmology science
Published: December 02, 2024
Safety and effectiveness of secukinumab in Japanese patients with generalized pustular psoriasis: A post-marketing surveillance.
Journal: The Journal of dermatology
Published: July 17, 2024
Safety and effectiveness of secukinumab subcutaneous injection in Japanese patients with psoriasis vulgaris and psoriatic arthritis: A post-marketing surveillance.
Journal: The Journal of dermatology
Published: May 20, 2024
Long-term efficacy and safety of canakinumab in the treatment of systemic juvenile idiopathic arthritis in Japanese patients: Results from an open-label Phase III study.
Journal: Modern rheumatology
Published: May 11, 2022
Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real-world evidence in Japan.
Journal: The Journal of dermatology
Published: June 30, 2020
Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients.
Journal: Modern rheumatology
Published: June 20, 2020
Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma.
Journal: Allergology international : official journal of the Japanese Society of Allergology
Published: March 15, 2016
Last Updated: 09/26/2026